Efficacy of Remifentanil in Patients Undergoing Cardiac Surgery: A Systematic Review and Network Meta-Analysis

Area of Science:

• Anesthesiology
• Critical Care Medicine
• Pharmacology

Background:

• Remifentanil is an ultra-short-acting opioid used globally in postcardiac surgery.
• Previous research has compared remifentanil to other opioids but not in a direct, single-opioid comparison context.
• Understanding remifentanil's impact on mechanical ventilation duration is crucial for optimizing patient recovery after cardiac surgery.

Purpose of the Study:

• To evaluate if remifentanil shortens mechanical ventilation (MV) duration in adult patients following cardiac surgery.
• To compare the efficacy of remifentanil against specific single opioids in the postcardiac surgery intensive care unit setting.

Main Methods:

• A systematic review and frequentist network meta-analysis of randomized controlled trials were conducted.
• Studies included adults (≥18 years) admitted to the ICU after cardiac surgery, comparing various opioids.
• The primary outcome was the duration of mechanical ventilation (MV), with a 60-minute reduction considered significant.

Main Results:

• Eight randomized controlled trials were identified and analyzed.
• No significant difference in MV duration was found between remifentanil and fentanyl (MD 0.09 min), morphine (MD -19 min), or sufentanil (MD -2.44 min).
• The confidence intervals for all comparisons were wide, indicating substantial uncertainty.

Conclusions:

• Remifentanil does not appear to reduce mechanical ventilation times in patients after cardiac surgery.
• Current evidence suggests remifentanil offers no advantage over other commonly used opioids in shortening MV duration in this population.
• Further research may be needed to explore potential nuances or specific patient subgroups.